These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35807233)

  • 1. Sustainable Protocol for the Synthesis of 2',3'-Dideoxynucleoside and 2',3'-Didehydro-2',3'-dideoxynucleoside Derivatives.
    Martín-Nieves V; Sanghvi YS; Fernández S; Ferrero M
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.
    Balzarini J
    Pharm World Sci; 1994 Apr; 16(2):113-26. PubMed ID: 8032337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-human immunodeficiency virus type 1 activities of dideoxynucleoside phosphotriester derivatives in primary monocytes/macrophages.
    Thumann-Schweitzer C; Gosselin G; Périgaud C; Benzaria S; Girardet JL; Lefebvre I; Imbach JL; Kirn A; Aubertin AM
    Res Virol; 1996; 147(2-3):155-63. PubMed ID: 8901435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
    Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ddI and d4T plus protease inhibitors.
    GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
    Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues.
    Sommadossi JP
    J Infect Dis; 1995 Mar; 171 Suppl 2():S88-92. PubMed ID: 7861023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells.
    Cui L; Locatelli L; Xie MY; Sommadossi JP
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1228-34. PubMed ID: 9067308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy of human immunodeficiency virus-related disease.
    Mitsuya H; Yarchoan R; Kageyama S; Broder S
    FASEB J; 1991 Jul; 5(10):2369-81. PubMed ID: 1712326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation.
    Kim DD; Chien YW
    J Pharm Sci; 1995 Sep; 84(9):1061-6. PubMed ID: 8537882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antiviral activity of didanosine compared with that of other dideoxynucleoside analogs against laboratory strains and clinical isolates of human immunodeficiency virus.
    Hitchcock MJ
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S16-21. PubMed ID: 8425017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine (3TC) phosphorylation and drug interactions in vitro.
    Kewn S; Veal GJ; Hoggard PG; Barry MG; Back DJ
    Biochem Pharmacol; 1997 Sep; 54(5):589-95. PubMed ID: 9337075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
    Benbrik E; Chariot P; Bonavaud S; Ammi-Saïd M; Frisdal E; Rey C; Gherardi R; Barlovatz-Meimon G
    J Neurol Sci; 1997 Jul; 149(1):19-25. PubMed ID: 9168161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What they say about nucleoside drugs.
    Posit Aware; 1999; 10(1):28-34. PubMed ID: 11366520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
    Cinatl J; Cinatl J; Weber B; Rabenau H; Weissflog A; Mainke M; Kornhuber B; Doerr HW
    Acta Virol; 1993 Oct; 37(5):360-8. PubMed ID: 8184788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
    Rey D; Schmitt AC; Schmitt MP; Partisani M; Nicolle M; Kempf-Durepaire G; Krantz V; Lang JM
    Presse Med; 1998 Feb; 27(8):360. PubMed ID: 9768003
    [No Abstract]   [Full Text] [Related]  

  • 20. Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
    Phillips AN; Katlama C; Barton S; Vella S; Blaxhult A; Clotet B; Goebel FD; Hirschel B; Pedersen C; Lundgren JD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):239-44. PubMed ID: 9495224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.